Anti-dementia medications: Current prescriptions in clinical practice and new agents in progress

Therapeutic Advances in Drug Safety

Volumn 6, Issue 4, 2015, Pages 151-165

  Stella, Florindo ^a,b   Radanovic, Márcia ^a   Canineu, Paulo Renato ^a   de Paula, Vanessa J R ^a   Forlenza, Orestes V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Alzheimer's disease; cognitive impairment; dementia; pharmacology; treatment

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APIGENIN; ASCORBIC ACID PLUS VITAMIN B COMPLEX; AVAGACESTAT; BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; CRENEZUMAB; CURCUMIN; DONEPEZIL; FLORBETAPIR F 18; GALANTAMINE; GANTENERUMAB; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LITHIUM; MEMANTINE; NOOTROPIC AGENT; OMEGA 3 FATTY ACID; PLACEBO; PONEZUMAB; RIVASTIGMINE; SEMAGACESTAT; SOLANEZUMAB; TENILSETAM; UNINDEXED DRUG; VANUTIDE CRIDIFICAR; VITAMIN B GROUP;

AEROBIC EXERCISE; AGITATION; ALZHEIMER DISEASE; ASEPTIC MENINGITIS; BRADYCARDIA; BRAIN ATROPHY; BRAIN EDEMA; BRAIN HEMORRHAGE; COGNITIVE RESERVE; DEMENTIA; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; ENCEPHALITIS; FAINTNESS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; IMMUNOTHERAPY; INSOMNIA; MENINGOENCEPHALITIS; MILD COGNITIVE IMPAIRMENT; NAUSEA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NON MELANOMA SKIN CANCER; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SKIN DISEASE; SOCIAL INTERACTION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 84938349981     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098615592116     Document Type: Review

References (57)

1. Adolfsson O. Pihlgren M. Toni N. Varisco Y. Buccarello A. Antoniello K. (2012) An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32: 9677–9689.
2. Amanatkar H. Grossberg G. (2014) Transdermal rivastigmine in the treatment of Alzheimer–s disease: current and future directions. Expert Rev Neurother 14: 1119–1125.
3. Annweiler C. Beauchet O. (2012) Possibility of a new anti-Alzheimer–s disease pharmaceutical composition combining memantine and vitamin D. Drugs Aging 29: 81–91.
4. Birks J. (2006) Cholinesterase inhibitors for Alzheimer–s disease. Cochrane Database Syst Rev 25: CD005593.
5. Braak H. Del Tredici K. (2011) The pathological process underlying Alzheimer–s disease in individuals under thirty. Acta Neuropathol 121: 171–181.
6. Christensen D. (2012) Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer–s disease. Postgrad Med 124: 110–116.
7. Coric V. van Dyck C. Salloway S. Andreasen N. Brody M. Richter R. (2012) Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69: 1430–1440.
8. Cummings J. Cho W. Ward M. Friesenhahn M. Brunstein F. Honigberg L. (2014) A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer–s disease. Alzheimer–s Association International Conference, Copenhagen, Denmark, presentation number: O4-11-06.
9. Davis J. Couch R. (2014) Strategizing the development of Alzheimer–s therapeutics. Adv Alzheimer Dis 3: 107–127.
10. Devanand D. (2014) Whatever happened to new treatments for Alzheimer–s disease? J Clin Psychiatry 75: 775–776.
11. Di Santo S. Prinelli F. Adorni F. Caltagirone C. Musicco M. (2013) A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer–s disease. J Alzheimers Dis 35: 349–361.
12. Doody R. Raman R. Farlow M. Iwatsubo T. Vellas B. Joffe S. (2013) A phase 3 trial of semagacestat for treatment of Alzheimer–s disease. N Engl J Med 369: 341–350.
13. Doody R. Thomas R. Farlow M. Iwatsubo T. Vellas B. Joffe S. (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer–s disease. N Engl J Med 370: 311–321.
14. Douaud G. Refsum H. de Jager C. Jacoby R. Nichols T. Smith S. (2013) Preventing Alzheimer–s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110: 9523–9528.
15. Dubois B. Feldman H. Jacova C. Hampel H. Molinuevo J. Blennow K. (2014) Advancing research diagnostic criteria for Alzheimer–s disease: the IWG-2 criteria. Lancet Neurol 613: 614–629.
16. Forlenza O. Diniz B. Radanovic M. Santos F. Talib L. Gattaz W. (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomized controlled trial. Br J Psychiatry 198: 351–356.
17. Gauthier S. Leuzy A. Racine E. Rona-Neto P. (2013) Diagnosis and management of Alzheimer–s disease: past, present and future ethical issues. Prog Neurobiol 110: 102–113.
18. Gauthier S. Patterson C. Chertkow H. Gordon M. Herrmann N. Rockwood K. (2012) Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J 15: 120–126.
19. Gauthier S Schlaefke S. (2014) Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging 28: 2065–2077.
20. Gilman S. Koller M. Black R. Jenkins L. Griffith S. Fox N. (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553–1562.
21. Grossberg G. (2003) Cholinesterase inhibitors for the treatment of Alzheimer–s disease: getting on and staying on. Curr Ther Res Clin Exp 64: 216–235.
22. Grossberg G. Manes F. Allegri R. Gutiérrez-Robledo L. Gloger S. Xie L. (2013) The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo- controlled trial in patients with moderate-to-severe Alzheimer–s disease taking cholinesterase inhibitors. CNS Drugs 27: 469–478.
23. Herrmann A. Spires-Jones T. (2015) Clearing the way for tau immunotherapy in Alzheimer–s disease. J Neurochem 132: 1–4.
24. Hwang S. Shin E. Shin T. Lee B. Choi S. Kang J. (2012) Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer–s disease-related neuropathies: involvement of non-amyloidogenic processing. J Alzheimers Dis 31: 207–223.
25. Ihl R. Perisic I. Maurer K. Dierks T. (1989) Effects of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm Park Dis Dement Sect 1: 84–85.
26. Istace A. Bracoud L. Berman R. Luo F. Roche F. Salloway S. (2014) Volumetric MRI results of BMS avagacestat in a prodromal AD population. Alzheimer–s Association International Conference, Copenhagen, Denmark, presentation number: IC-P-108.
27. Jack C. Jr. Wiste H. Knopman D. Vemuri P. Mielke M. Weigand S. (2014) Rates of b-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 82: 1605–1612.
28. Kamphuis P. Verhey F. Olde Rikkert M. Twisk J. Swinkels S. Scheltens P. (2011) Efficacy of a medical food on cognition in Alzheimer–s disease: results from secondary analyses of a randomized, controlled trial. J. Nutr. Health Aging 15: 720–724.
29. Kivipelto M. Mangialasche F. Solomon A. Johansson G. Lannfelt L. Fratiglioni L. (2014) Ninth key symposium introduction: updating Alzheimer–s disease diagnosis implications for prevention and treatment. J Intern Med 275: 202–203.
30. Kontsekova E. Zilka N. Kovacech B. Skrabana R. Novak M. (2014) Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer–s disease. Alzheimer Res Ther 6: 1–16.
31. Lambracht-Washington D. Rosenberg R. (2013) Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease. Immunotargets Ther 2: 105–114.
32. Landau S. Marks S. Mormino E. Rabinovici G. Oh H. O–Neil J. (2012) Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol 69: 623–629.
33. Landen J. Zhao Q. Cohen S. Borrie M. Woodward M. Billing C. (2013) Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol 36: 14–23.
34. Laske C. (2014) Correspondence: Phase 3 trials of solanezumab and bapineuzumab for Alzheimer–s disease, N Engl J Med 370: 1459–1460.
35. Li F. Shen L. Ji H. (2012) Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer–s disease: a meta-analysis. J Alzheimers Dis 31: 253–258.
36. McClure R. Yanagisawa D. Stec D. Abdollahian D. Koktysh D. Xhillari D. (2015) Inhalable curcumin: offering the potential for translation to imaging and treatment of Alzheimer–s disease. J Alzheimers Dis 44: 283–295.
37. Menting K. Claassen J. (2014) β-Secretase inhibitor; a promising novel therapeutic drug in Alzheimer–s disease. Front Aging Neurosci 6: 165.
38. Mikulca J. Nguyen V. Gajdosik D. Teklu S. Giunta E. Lessa E. (2014) Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharmacy Therapeutics 39: 25–37.
39. Millington C. Sonego S Karunaweera N. Rangel A. Aldrich-Wright J. Campbell I. (2014) Chronic neuroinflammation in Alzheimer–s disease: new perspectives on animal models and promising candidate drugs. Biomed Res Int 2014: article ID 309129.
40. Mills S. Mallmann J. Santacruz A. Fuqua A. Carril M. Aisen P. (2013) Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 169: 737–743.
41. Moreth J. Mavoungou C. Schindowski K. (2103) Passive anti-amyloid immunotherapy in Alzheimer–s disease: what are the most promising targets? Immun Ageing 10: 18.
42. Nunes P. Forlenza O. Gattaz W. (2007) Lithium and risk for Alzheimer–s disease in elderly patients with bipolar disorder. Br J Psychiatry 190: 359–360.
43. O–Brien J. Burns A. (2011) Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 25: 997–1019.
44. Ostrowitzki S. Deptula D. Thurfjell L. Barkhof F. Bohrmann B. Brooks D.(2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69: 198–207.
45. Panza F. Solfrizzi V. Imbimbo B. Giannini M. Santamato A. Seripa D. (2014) Efficacy and safety studies of gantenerumab in patients with Alzheimer–s disease. Expert Rev Neurother 14: 973–986.
46. Perry E. Perry R. Blessed G. Tomlinson B. (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1: 189.
47. Recuero M. Serrano E. Bullido M. Valdivieso F. (2004) Abeta production as consequence of cellular death of a human neuroblastoma overexpressing APP. FEBS Lett 3: 114–118.
48. Reiman E. Langbaum J. Tariot P. (2014) Endpoints in preclinical Alzheimer–s disease trials. J Clin Psychiatry 75: 661–662.
49. Reisberg B. Doody R. Stöffler A. Schmitt F. Ferris S. Möbius H. (2003) Memantine in moderate-to-severe Alzheimer–s disease. N Engl J Med 348: 1333–1341.
50. Roberts G. Gentleman S. Lynch A. Murray L. Landon M. Graham D. (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer–s disease. J Neurol Neurosurg Psychiatry 57: 419–425.
51. Salloway S. Sperling R. Fox N. Blennow K. Klunk W. Raskind M. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer–s disease. N Engl J Med 2014 370: 322–333.
52. Sofi F. Valecchi D. Bacci D. Abbate R. Gensini G. Casini A. (2011) Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med 269: 107–117.
53. Sperling R. Mormino E. Johnson K. (2014) The evolution of preclinical Alzheimer–s disease: implications for prevention trials. Neuron 84: 608–622.
54. Sperling R. Salloway S. Brooks D. Tampieri D. Barakos J. Fox N. (2012) Amyloid-related imaging abnormalities in patients with Alzheimer–s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11: 241–249.
55. Winblad B. Gauthier S. Aström D. Stender K. (2010) Memantine benefits functional abilities in moderate to severe Alzheimer–s disease. J Nutr Health Aging 14: 770–774.
56. Winblad B. Graf A. Riviere M. Andreasen N. Ryan J. (2014) Active immunotherapy options for Alzheimer–s disease. Alzheimer Res Ther 6: 7.
57. Zhao L. Wang J. Liu R. Li X. Li J. Zhang L. (2013) Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer–s disease mouse model. Molecules 18: 9949–9965.